Which information must be specified about treatments for each trial group?

• A. Names of all products only
• B. Names of all products, doses, dosing schedules, routes, and treatment periods for each group
• C. The storage conditions for each product
• D. The adverse event reporting timeline

Answer: (B)

In GCP, the description of how participants are treated in each group must spell out exactly what exposure they will have to the interventions. This means naming all products used, and detailing the doses, how often they’re given (dosing schedules), how they’re administered (routes), and how long the treatment lasts (treatment periods). Providing this complete information ensures the regimen is implemented consistently across sites, allows accurate calculation of each participant’s exposure, supports interpretation of efficacy and safety results, and enables clear regulatory and ethical review.

Storage conditions and the timeline for reporting adverse events are important for safety and handling, but they are separate from the specific treatment regimen itself. They belong in other parts of the trial documentation (like product handling procedures and safety monitoring plans) rather than in the treatment-description details.